SMYD4抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08786(SMYD4 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08786(SMYD4 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

SMYD4 (SET and MYND domain-containing protein 4) is a member of the SMYD protein family, characterized by a conserved SET domain responsible for methyltransferase activity and a MYND domain involved in protein-protein interactions. Unlike other SMYD family members, which are often linked to cancer progression, SMYD4 is proposed to act as a tumor suppressor. Studies suggest its role in regulating gene expression through histone methylation, particularly H3K4 and H3K36 methylation, influencing cellular processes like differentiation, apoptosis, and DNA repair. SMYD4 is highly expressed in neural tissues, implicating its importance in neurodevelopment, and its dysregulation has been associated with neurodevelopmental disorders and neurodegenerative diseases.

SMYD4 antibodies are critical tools for studying its expression, localization, and molecular interactions. They enable detection via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Research using these antibodies has revealed reduced SMYD4 expression in certain cancers, such as glioblastoma and neuroblastoma, often linked to promoter hypermethylation or genomic deletions. Additionally, SMYD4 antibodies aid in exploring its regulatory networks, including interactions with transcription factors and chromatin-modifying complexes. Ongoing studies aim to clarify SMYD4’s functional mechanisms and therapeutic potential, particularly in contexts of tumor suppression and neurological health.